[HTML][HTML] Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation

WK Kim, AJ Buckley, DH Lee, A Hiroto… - Nature …, 2024 - nature.com
Androgen deprivation therapy (ADT) targeting androgen/androgen receptor (AR)-signaling
pathways is the main therapy for advanced prostate cancer (PCa). However, ADT eventually …

[HTML][HTML] LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function

A Kumaraswamy, Z Duan, D Flores, C Zhang… - JCI insight, 2023 - ncbi.nlm.nih.gov
Abstract Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes
stemness and cell survival in cancers such as prostate cancer. Most prostate malignancies …

[HTML][HTML] The Multifaceted Role of Osteopontin in Prostate Pathologies

SV Silver, P Popovics - Biomedicines, 2023 - mdpi.com
The prostate gland, located beneath the bladder and surrounding the proximal urethra in
men, plays a vital role in reproductive physiology and sexual health. Despite its importance …

Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer …

M Zhang, M Sjöström, X Cui, A Foye, K Farh… - Nature Cell …, 2024 - nature.com
Transcription factor (TF) proteins regulate gene activity by binding to regulatory regions,
most importantly at gene promoters. Many genes have alternative promoters (APs) bound by …

ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer

C Qian, Q Yang, M Rotinen, R Huang… - Nucleic Acids …, 2024 - academic.oup.com
Abstract Androgen receptor-(AR-) indifference is a mechanism of resistance to hormonal
therapy in prostate cancer (PC). Here we demonstrate that ONECUT2 (OC2) activates …

[HTML][HTML] ONECUT2 activates diverse resistance drivers of androgen receptor-independent heterogeneity in prostate cancer

C Qian, Q Yang, M Rotinen, R Huang, H Kim, B Gallent… - bioRxiv, 2023 - ncbi.nlm.nih.gov
Abstract Androgen receptor-(AR-) indifference is a mechanism of resistance to hormonal
therapy in prostate cancer (PC). Here we demonstrate that the HOX/CUT transcription factor …

[HTML][HTML] Epigenetic disruption of the RARγ complex impairs its function to bookmark AR enhancer interactions required for enzalutamide sensitivity in prostate cancer

SA Wani, S Hussain, JS Gray, D Nayak, H Tang… - bioRxiv, 2023 - ncbi.nlm.nih.gov
The current study in prostate cancer (PCa) focused on the genomic mechanisms at the cross-
roads of pro-differentiation signals and the emergence of lineage plasticity. We explored an …

[HTML][HTML] Unravelling the Role of Iroquois Homeobox 4 and its Interplay with Androgen Receptor in Prostate Cancer

P Janaththani, G Tevz, A Fernando, A Malik… - Research …, 2023 - ncbi.nlm.nih.gov
Genome-wide association studies have linked Iroquois-Homeobox 4 (IRX4) as a robust
expression quantitative-trait locus associated with prostate cancer (PCa) risk. However, the …

[HTML][HTML] Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition

S Wilkinson, AT Ku, RT Lis, IM King, D Low, SY Trostel… - medRxiv, 2024 - ncbi.nlm.nih.gov
Patients diagnosed with localized high-risk prostate cancer have higher rates of recurrence,
and the introduction of neoadjuvant intensive hormonal therapies seeks to treat occult …

[引用][C] Epigenetic regulation of androgen dependent and independent prostate cancer

J Mishra, S Chakraborty, P Nandi, S Manna, T Baral… - 2024 - Elsevier